Navigation Links
Delcath to Present at the 30th Annual Canaccord Global Growth Conference
Date:8/4/2010

ystemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers.  Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system.  For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug-delivery system for the treatment of other liver cancers and other organs, market acceptance and the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenu
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... BAKERSFIELD, Calif. , Sept. 1, 2015 /PRNewswire/ ... Chronic Care Management (CCM) and Drug Adherence m ... monitoring help automate the process of non face-to-face ... "With this new release of our apps, ... care management services along with our ONCHIT certified ...
(Date:9/1/2015)... LOS ANGELES , Sept. 1, 2015 /PRNewswire/ ... biopharmaceutical research and development company specializing in oncology, ... Chairman and Chief Executive Officer, and David ... Investor Relations, will present a corporate overview at ... spotlight the biotechnology and healthcare industries: the FBR ...
(Date:9/1/2015)... 31, 2015 Research and Markets ( ... "Introduction to Veterinary Pharmacovigilance (London, UK - ... This course has been designed to ... those concerned with Veterinary Pharmacovigilance. New entrants, support ... a better understanding of veterinay drug safety will ...
Breaking Medicine Technology:SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4Introduction to Veterinary Pharmacovigilance Seminar (London, UK - September 23-24) 2
... Depomed, Inc. (NASDAQ: DEPO ) today ... payment from Ironwood Pharmaceuticals, Inc. following the development and ... candidate meeting pre-specified attributes under its Research Collaboration and ... in July 2011. Under the terms of the agreement, Depomed ...
... China, May 11, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... a leading pharmaceutical company specializing in the development, manufacturing, ... today announced that the annual general meeting of shareholders ... 2012 at 10 a.m. Beijing time. The meeting will ...
Cached Medicine Technology:Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc. 2Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2
(Date:9/2/2015)... ... 2015 , ... On September 9, 2015, over 27,000 people from all over ... convention to date for the state of Utah. , “We are thrilled with the ... David Stirling, doTERRA CEO. “One of the most exciting elements of our convention is ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Brain Aneurysm Awareness Month , which was established by the Foundation in ... awareness and education, and helping fund more research remains our top priority,” commented ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to ... are being launched, and mobile device usage as a whole is something people around ... personal lives. What's more people are expecting mobile versions of their favorite software. , ...
(Date:9/1/2015)... ... 2015 , ... September is National Prostate Cancer Awareness Month and Florida Hospital ... each year in the United States. , Prostate cancer is to men what breast ... 1 in 7 men. One new case occurs every 2.3 minutes and a man ...
(Date:9/1/2015)... ... 2015 , ... According to a study published August 25th in ... in a three year study about weight loss and diabetes were far more likely ... loss surgery at the onset of the trial. In fact, the participants in the ...
Breaking Medicine News(10 mins):Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2
... Veteran,s charity supports Obama administration,s announcement of plan ... system available to wounded veterans , OSSINING, N.Y., ... Salute America,s Heroes , a leading non-partisan, ... veterans returning from Iraq and Afghanistan and their ...
... FRANCISCO, April 9 Burrill & Company, a San ... principal activities in Venture Capital, Private Equity, Merchant Banking ... promotions: , Tiba Aynechi to Director, Merchant Banking ... Patel to Senior Associate, Merchant Banking Tiba Aynechi ...
... previous obesity , , THURSDAY, April 9 (HealthDay News) -- ... at increased risk for physical disabilities, even if they,ve shed ... a new U.S. study. , "In both men and women, ... developing mobility limitations in old age, and the longer they ...
... Legacy Foundation(R) and ASPCA(R) Urge Pet Owners to Safeguard Their ... April 9 The American Legacy Foundation(R) is challenging pet ... of April, which kicks off Prevention of Cruelty to Animals ... safe levels of exposure to secondhand smoke -- for humans ...
... Largest Breast Cancer Organization Investing $60 Million to Research Despite ... Testing whether a powerful ingredient in marijuana can help slow ... of six Bay Area breast cancer studies being funded this ... leader in the breast cancer movement announced today. The projects ...
... touts five of the first 23 recognized facilities.MILWAUKEE, April 9 ... is home to five breast centers out of ... Program for Breast Centers ( NAPBC ), a ... http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b )The first facility named in Wisconsin, was ...
Cached Medicine News:Health News:Coalition to Salute America's Heroes(TM) Applauds President's Announcement to Create Joint Virtual Lifetime Records 2Health News:Burrill & Company Announces Promotions 2Health News:Extra Pounds in Mid-Life Affect Later Mobility 2Health News:Tobacco is Toxic for Toto Too 2Health News:Tobacco is Toxic for Toto Too 3Health News:N. California Researchers Testing Whether Marijuana Chemical Can Slow Cancer Growth, With Funding by Susan G. Komen for the Cure(R) 2Health News:N. California Researchers Testing Whether Marijuana Chemical Can Slow Cancer Growth, With Funding by Susan G. Komen for the Cure(R) 3Health News:Aurora Health Care Breast Centers Receive National Recognition 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: